echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > IMS developed Q1 hospital market performance in 2015: the growth rate reached the lowest point, Pfizer AstraZeneca Qilu ranked the top three

    IMS developed Q1 hospital market performance in 2015: the growth rate reached the lowest point, Pfizer AstraZeneca Qilu ranked the top three

    • Last Update: 2015-11-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Source: according to statistics of overall market performance of Hermes 2015-11-17, the total sales volume of Chinese hospital medicine market in the first quarter of 2015 was 154.2 billion yuan (data source: IMS Hermes China Hospital Medicine statistical report ≥ 100 beds), up 7.1% compared with the same period last year, reaching 2012 The lowest quarterly growth rate since the growth of the pharmaceutical market slowed down in the fourth quarter of

    The trough of this quarter is actually a continuous performance of market growth affected by policies in recent years

    In addition, in 2015, 1 At the end of this month, the notice on further improving the action plan of medical services issued by the health and Family Planning Commission once again emphasized the strengthening of rational drug use and vigorously promoting the clinical pathway, ranging from the spread of antibacterial drugs to hormone drugs, anti-tumor drugs and auxiliary drugs, aiming to strengthen the clinical use of dry preparation, promote individualized drug use, and reduce the drug damage of patients

    Under such a heavy blow, let China The pharmaceutical industry is full of challenges in 2015

    Based on the 12-month mat (rolling full year data), the mat growth rate in the first quarter of 2015 was 10.2%, and the growth slowdown continued

    *Sales volume: purchase amount of hospital pharmacy; * mat (rolling annual data): the sum of data traced back 12 months from the specified time node, which refers to the sales volume from the second quarter of 2014 to the first quarter of 2015

    The market performance of multinational enterprises and domestic enterprises is affected by a new round of policies

    The quarterly growth rate of domestic enterprises and multinational enterprises has declined significantly in the first quarter of 2015

    The growth rate of multinational enterprises has declined from 14.1% in the first quarter of 2014 to 5.2% in this quarter, and that of local enterprises is only 7.8% in this quarter

    According to the quarterly sales of the enterprise, among the top ten enterprises, the pharmaceutical industry of Yangtze River surpassed Sanofi in this quarter, ranking fifth

    At the city level, compared with the same period in the first quarter of 2014, the growth of tier two and tier three cities dropped significantly in the first quarter of 2015, from 13.7% to 7.5% for tier two cities and from 17.8% to 5.6% for tier three cities In fact, this is also a true reflection of the overall market situation

    In the second and third tier cities, especially the third tier cities, the products of local enterprises are the main competitiveness of local enterprises

    In recent years, the growth of traditional Chinese medicine has been continuously declining under the influence of successive policies

    In addition, the government's control over the overall pharmaceutical market has been strengthened

    Under multiple functions, the market performance of low-level cities is affected by the local market The implications of the decline in business growth are worrying

    First tier cities: Beijing, Shanghai, Guangzhou; second tier cities: Chengdu, Shenyang, Chongqing, Tianjin, Nanjing, Hangzhou, Shenzhen, Jinan, Zhengzhou, Wuhan, Ningbo, Harbin, Xi'an, Changsha, Pearl River Delta, Fuxia spring; third tier cities: Changzhou, Taiyuan, Dalian, Qingdao, Urumqi, Wuxi, Changchun, Shijiazhuang, Guiyang, Nanning, Kunming, Shaoxing, Wenzhou Taizhou, Jinhua, Jiaxing, Yantai, Nantong, Yangzhou, Xuzhou and Nanyang

    From the perspective of products, the market performance of main products and key treatment areas is affected by the overall pharmaceutical market environment in this quarter, and the growth rate of each product is basically lower than that in the previous quarter, especially Xiyanping

    Influenced by the double effects of the traditional Chinese medicine market and the overall market, the growth rate is down to - 10.7% from 6.2% in the previous quarter

    Similarly, in terms of major areas, the growth of product sales in this quarter is also lower than that in the previous quarter

    In particular, the growth of traditional Chinese medicine, antibiotics, anti-tumor drugs and infusion products is more obvious because of the greater efforts of policy control

    After several years of traditional Chinese medicine replacing antibiotics as the largest segment of the Chinese hospital market, although the market environment is under great pressure, it can still maintain its position as the largest treatment field relying on the huge volume

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.